Treatment for chronic hepatitis C in a cohort of opiate substitution therapy recipients in three Swedish cities - Completion rates and efficacy

European Journal of Gastroenterology and Hepatology

Volumn 26, Issue 5, 2014, Pages 523-531

  Jerkeman, Anna ^a   Norkrans, Gunnar ^c   Lidman, Christer ^e   Westin, Johan ^c   Lagging, Martin ^c   Frimand, Jan ^b   Simonsberg, Christian ^d   Kakko, Johan ^f   Widell, Anders ^b   Björkman, Per ^a  

^a LUND UNIVERSITY   (Sweden)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

^c UNIVERSITY OF GOTHENBURG   (Sweden)

^d SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^e KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^f Stockholm Center for Dependency Disorders   (Sweden)

Author keywords

depression; health related quality of life; hepatitis C; opiate substitution; treatment completion

Indexed keywords

PEGINTERFERON ALPHA2B; RIBAVIRIN; ANTIVIRUS AGENT;

ADULT; AGE; ANEMIA; ANTIVIRAL THERAPY; ARTICLE; CAUSE OF DEATH; COHORT ANALYSIS; DECOMPENSATED LIVER CIRRHOSIS; DEPRESSION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; FATIGUE; FEASIBILITY STUDY; FEMALE; FLU LIKE SYNDROME; GASTROENTERITIS; HEMATOLOGIC DISEASE; HEPATIC ENCEPHALOPATHY; HEPATITIS C; HUMAN; LIVER FAILURE; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; MONTGOMERY ASBERG DEPRESSION RATING SCALE; MOOD CHANGE; MOOD DISORDER; NAUSEA; OPIATE SUBSTITUTION TREATMENT; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PSYCHOSIS; QUALITY OF LIFE; RECIPIENT; RELAPSE; SHORT FORM 36; SLEEP DISORDER; SUICIDAL IDEATION; SWEDEN; TREATMENT DURATION; TREATMENT RESPONSE; VIRUS LOAD; ATTITUDE TO HEALTH; CLINICAL TRIAL; COMORBIDITY; DIAGNOSIS; DRUG THERAPY; DRUG USE; EPIDEMIOLOGY; HEPATITIS C, CHRONIC; INCIDENCE; MIDDLE AGED; MULTICENTER STUDY; OPIOID-RELATED DISORDERS; PSYCHOLOGY; QUESTIONNAIRE; SUBSTANCE ABUSE; TIME; TREATMENT OUTCOME;

ADULT; ANTIVIRAL AGENTS; COMORBIDITY; DEPRESSION; DRUG USERS; FEASIBILITY STUDIES; FEMALE; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HEPATITIS C, CHRONIC; HUMANS; INCIDENCE; MALE; MEDICATION ADHERENCE; MIDDLE AGED; OPIATE SUBSTITUTION TREATMENT; OPIOID-RELATED DISORDERS; PROSPECTIVE STUDIES; QUALITY OF LIFE; QUESTIONNAIRES; SUBSTANCE ABUSE, INTRAVENOUS; SWEDEN; TIME FACTORS; TREATMENT OUTCOME;

EID: 84898475728     PISSN: 0954691X     EISSN: 14735687     Source Type: Journal    
DOI: 10.1097/MEG.0000000000000076     Document Type: Article

References (35)

1. Omland LH, Jepsen P,Weis N, Christensen PB, Laursen AL, Nielsen H, et al. Mortality in HIV-infected injection drug users with active vs cleared hepatitis C virus-infection: a population-based cohort study. J Viral Hepat 2010; 17:261-268.
2. Kielland KB, Skaug K, Amundsen EJ, Dalgard O. All-cause and liver-related mortality in hepatitis C infected drug users followed for 33 years: a controlled study. J Hepatol 2013; 58:31-37.
3. Duberg AS, Torner A, Davidsdottir L, Aleman S, Blaxhult A, Svensson A, et al. Cause of death in individuals with chronic HBV and/or HCV infection, a nationwide community-based register study. J Viral Hepat 2008; 15: 538-550.
4. El-Kamary SS, Jhaveri R, Shardell MD. All-cause, liver-related, and non-liver-related mortality among HCV-infected individuals in the general US population. Clin Infect Dis 2011; 53:150-157.
5. Singal AG, Volk ML, Jensen D, Di Bisceglie AM, Schoenfeld PS. A sustained viral response is associated with reduced liver-related morbidity and mortality in patients with hepatitis C virus. Clin Gastroenterol Hepatol 2010; 8:280-288, 288.e281.
6. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL Jr, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347:975-982.
7. Hadziyannis SJ, Sette H Jr, Morgan TR, Balan V, Diago M, Marcellin P, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140:346-355.
8. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358:958-965.
9. Pawlotsky JM. Treatment of chronic hepatitis C: current and future. Curr Top Microbiol Immunol 2013; 369:321-342.
10. National Institutes of Health Consensus Development Conference Statement. Management of hepatitis C: 2002 - June 10-12, 2002. Hepatology 2002; 36:S3-S20.
11. Grebely J, Dore GJ. Hepatitis C: enhancing treatment for hepatitis C among drug users. Nat Rev Gastroenterol Hepatol 2011; 8:11-13.
12. Hellard M, Sacks-Davis R, Gold J. Hepatitis C treatment for injection drug users: a review of the available evidence. Clin Infect Dis 2009; 49: 561-573.
13. Grebely J, Bruggmann P, Backmund M, Dore GJ. Moving the agenda forward: the prevention and management of hepatitis C virus infection among people who inject drugs. Clin Infect Dis 2013; 57 (Suppl 2): S29-S31.
14. McGowan CE, Fried MW. Barriers to hepatitis C treatment. Liver Int 2012 (Suppl 1):151-156.
15. Gronbladh L, Ohlund LS, Gunne LM. Mortality in heroin addiction: impact of methadone treatment. Acta Psychiatr Scand 1990; 82:223-227.
16. Gibson A, Degenhardt L, Mattick RP, Ali R,White J, O'Brien S. Exposure to opioid maintenance treatment reduces long-term mortality. Addiction 2008; 103:462-468.
17. Marsch LA. The efficacy of methadone maintenance interventions in reducing illicit opiate use, HIV risk behavior and criminality: a meta-analysis. Addiction 1998; 93:515-532.
18. Dimova RB, Zeremski M, Jacobson IM, Hagan H, Des Jarlais DC, Talal AH. Determinants of hepatitis C virus treatment completion and efficacy in drug users assessed by meta-analysis. Clin Infect Dis 2013; 56:806-816.
19. Jerkeman A, Westin J, Lagging M, Norkrans G, Lidman C, Frimand J, et al. Chronic hepatitis C in Swedish subjects receiving opiate substitution therapy - factors associated with advanced fibrosis. Scand J Inf Dis 2014 [Epub ahead of print].
20. McHorney CA,Ware JE Jr, Lu JF, Sherbourne CD. The MOS 36-item Short- Form Health Survey (SF-36): III. Tests of data quality, scaling assumptions, and reliability across diverse patient groups. Med Care 1994; 32:40-66.
21. Younossi Z, Kallman J, Kincaid J. The effects of HCV infection and management on health-related quality of life. Hepatology 2007; 45: 806-816.
22. Ryan CF, White JM. Health status at entry to methadone maintenance treatment using the SF-36 health survey questionnaire. Addiction 1996; 91:39-45.
23. Deering D, Frampton C, Horn J, Sellman D, Adamson S, Potiki T. Health status of clients receiving methadone maintenance treatment using the SF-36 health survey questionnaire. Drug Alcohol Rev 2004; 23: 273-280.
24. Ware JE Jr, Snow KK, Kosinski M, Gandek B. SF-36 health survey. Manual and interpretation guide. Boston, MA: The Health Institute; 1993.
25. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979; 134:382-389.
26. Schaefer M, Sarkar R, Knop V, Effenberger S, Friebe A, Heinze L, et al. Escitalopram for the prevention of peginterferon-alpha2a-associated depression in hepatitis C virus-infected patients without previous psychiatric disease: a randomized trial. Ann Intern Med 2012; 157:94-103.
27. McHutchison JG, Manns M, Patel K, Poynard T, Lindsay KL, Trepo C, et al. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology 2002; 123:1061-1069.
28. Davis GL, Alter MJ, El-Serag H, Poynard T, Jennings LW. Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterology 2010; 138:513-521, 521.e511-516.
29. Rein DB,Wittenborn JS,Weinbaum CM, Sabin M, Smith BD, Lesesne SB. Forecasting the morbidity and mortality associated with prevalent cases of pre-cirrhotic chronic hepatitis C in the United States. Dig Liver Dis 2011; 43:66-72.
30. Mehta SH, Genberg BL, Astemborski J, Kavasery R, Kirk GD, Vlahov D, et al. Limited uptake of hepatitis C treatment among injection drug users. J Community Health 2008; 33:126-133.
31. Grebely J, Genoway KA, Raffa JD, Dhadwal G, Rajan T, Showler G, et al. Barriers associated with the treatment of hepatitis C virus infection among illicit drug users. Drug Alcohol Depend 2008; 93:141-147.
32. Martinez AD, Dimova R, Marks KM, Beeder AB, Zeremski M, Kreek MJ, et al. Integrated internist - addiction medicine - hepatology model for hepatitis C management for individuals on methadone maintenance. J Viral Hepat 2012; 19:47-54.
33. Sullivan MKJ, Ware JE. SF-36 Health Survey: Swedish manual and interpretation guide. 2nd ed. Gothenburg: Sahlgrenska University Hospital; 2002.
34. White JM, Ryan CF, Ali RL. Improvements in retention rates and changes in client group with methadone maintenance streaming. Drug Alcohol Rev 1996; 15:83-88.
35. Hassanein T, Cooksley G, Sulkowski M, Smith C, Marinos G, Lai MY, et al. The impact of peginterferon alfa-2a plus ribavirin combination therapy on health-related quality of life in chronic hepatitis C. J Hepatol 2004; 40: 675-681.